![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Structured Product Merrill Lynch Dow Jones Euro Stoxx 50 Index Mitts | NYSE:MLB | NYSE | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.97 | 0.00 | 01:00:00 |
RNS Number:9814I M.L. Laboratories PLC 20 March 2003 For immediate release 20 March 2003 ML Laboratories PLC Clickhaler selected to deliver Japan's market leading asthma treatment ML Laboratories (MLB) announces today that its respiratory drug delivery subsidiary, Innovata Biomed (IB) has signed an agreement granting Otsuka Pharmaceutical Co., Ltd. (Otsuka), a leading Japanese healthcare company, an exclusive licence to deliver Japan's market leading asthma treatment, Meptin in IB's dry powder inhaler, Clickhaler in Japan and Spain. Meptin is currently sold internationally by Otsuka in pressurised inhaler form. In consideration IB will receive milestone payments and will supply inhalers to Otsuka. Clickhaler was selected by Otsuka following success in conducting, with IB's cooperation, feasibility testing of a Meptin Clickhaler product the early results of which have been presented at international meetings. Commenting on the agreement Otsuka's Operating Officer Masuhiro Yoshitake said: "Otsuka has been making refinements of delivery systems for our leading beta2 agonist Meptin in order to satisfy different demands and conditions of patients. After extensive evaluation and feasibility studies, we have chosen IB's Clickhaler. We strongly believe that this combination (Meptin in Clickhaler) will provide asthma patients with the most reliable, easy-to-use solution." IB's Managing Director Paul Ballington said: "We are delighted that following extensive testing Otsuka have chosen Clickhaler to deliver its leading asthma brand. This agreement adds further accreditation to our Clickhaler platform and is an endorsement of the strength of our fully industrialised product. Clickhaler provides pharmaceutical companies with a fast-to-market dry powder delivery system for their respiratory products. "Today's announcement supports Innovata Biomed's position as one of the leading independent providers of respiratory drug delivery technologies to the pharmaceutical industry." -ends- For further information please contact: Mr. Stuart Sim CEO, ML Laboratories PLC +44 (0) 1925 844 700 Ben Padovan Weber Shandwick Square Mile +44 (0) 20 7067 0700 Graham Herring More information about IB can be found at www.innovata-biomed.com More information about ML Laboratories plc can be found at www.mllabs.co.uk Notes to Editors: Otsuka's beta2 agonist, procaterol hydrochloride, is marketed for the treatment of asthma as Meptin. Two Clickhaler products Asmasal (salbutamol) and Asmabec (beclomethasone) are currently being marketed in Europe under the terms of a licensing agreement with Celltech and two further asthma preparations in Clickhaler; formoterol and budesonide, have been licensed to an un-named third party for Europe. In November 2002, IB announced the filing of the application for marketing authorisation for formoterol Clickhaler in Europe, the budesonide Clickhaler filing is anticipated in Quarter 2 2003 with launch anticipated in 2003 and 2004 respectively. IB, through its range of dry powder inhaler and formulation developments, provides inhaled drug delivery expertise for drug discoverers and powder technologists. IB's established technologies permit rapid proof-of-principle testing and provide already industrialised fast-to-market options. ML Laboratories plc ML is a biopharmaceutical product development company with a development pipeline of future products that include cancer treatments for liver, head, neck and prostate cancer, all of which are in the clinic and a pain management portfolio whose lead compound is being prepared to enter Phase III studies. In addition, ML has a portfolio of early stage related development projects which includes DNA vaccines, cancer killing systems and targeted drug delivery. ML's activities are supported by its existing growing income stream from products it has successfully developed and licensed to other pharmaceutical companies which include Baxter, Shire and Celltech. This information is provided by RNS The company news service from the London Stock Exchange END MSCZGGZFLGMGFZG
1 Year Mitchells & Butlers Chart |
1 Month Mitchells & Butlers Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions